• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Aminosaccharides
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Aminosaccharides

3-(L-4-amino-2-hydroxy-butyryl)kanamycin A (Amikacin Impurity A): A Comprehensive Overview

3-(L-4-amino-2-hydroxy-butyryl)kanamycin A, also referred to as Amikacin Impurity A, is a compound with the CAS number 50725-24-1. This compound is a derivative of kanamycin, a well-known aminoglycoside antibiotic, and has garnered significant attention in recent years due to its unique chemical properties and potential therapeutic applications. The compound is classified as an impurity in the production of amikacin, a semisynthetic derivative of kanamycin, which is widely used in clinical settings for treating various bacterial infections.

The structure of 3-(L-4-amino-2-hydroxy-butyryl)kanamycin A consists of a kanamycin backbone with a specific substituent at the 3-position. This substituent, L-4-amino-2-hydroxy-butyryl, introduces unique stereochemical and functional group properties that influence the compound's biological activity and pharmacokinetics. Recent studies have highlighted the importance of understanding the stereochemistry of such compounds, as it plays a critical role in their interaction with ribosomal targets and subsequent antimicrobial activity.

From a pharmacological perspective, Amikacin Impurity A exhibits distinct properties compared to its parent compound, kanamycin. Research has shown that this impurity may possess altered antimicrobial spectra and resistance profiles, making it an interesting candidate for further investigation in the development of novel antibiotics. Additionally, studies on its pharmacokinetics have revealed differences in absorption, distribution, metabolism, and excretion (ADME) parameters compared to amikacin, which could have implications for its therapeutic use.

Recent advancements in analytical techniques, such as high-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) spectroscopy, have enabled more precise characterization of 3-(L-4-amino-2-hydroxy-butyryl)kanamycin A. These techniques have provided deeper insights into its molecular structure and stability under various conditions, which are crucial for its potential application in drug development.

In terms of therapeutic applications, Amikacin Impurity A has shown promise in preclinical models for treating infections caused by multidrug-resistant bacteria. Its ability to target specific bacterial ribosomal sites with high affinity has been validated through in vitro studies, suggesting potential efficacy against pathogens that are resistant to conventional antibiotics.

However, challenges remain in translating these findings into clinical practice. Issues such as toxicity profiles, bioavailability, and potential drug-drug interactions need to be thoroughly investigated before 3-(L-4-amino-2-hydroxy-butyryl)kanamycin A can be considered for therapeutic use. Collaborative efforts between academic researchers and pharmaceutical companies are essential to overcome these hurdles and unlock the full potential of this compound.

In conclusion, 3-(L-4-amino-2-hydroxy-butyryl)kanamycin A (Amikacin Impurity A) represents an intriguing compound with significant potential in the field of antimicrobial therapy. Its unique chemical structure and biological properties make it a valuable subject for ongoing research aimed at addressing the global challenge of antibiotic resistance.

• 37517-28-5(Amikacin)
• 13007-32-4(Lacto-N-neotetraose)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)